Multi-drug resistant organisms (MRDOs), such as Methicillin-resistant Staphylococcus aureus (MRSA), due to antibiotic use are of significant concern. Not only hospitals, but also long-term care facilities, are particularly susceptible to the impact of antibiotic resistance. Dr. Paul Drinka, clinical professor of internal medicine and geriatrics at University of Wisconsin-Madison and the Medical College of Wisconsin-Milwaukee, tells us that one evidence-based approach is to maintain a database of the MRDOs that will help identify clustering of a specific isolate and document a facility's resistance problem, which can then be addressed more precisely. What other specific steps might facilities take to prevent unnecessary use of antibiotics and therefore limit resistance? Dr. Eric Tangalos hosts.
Ticking Time Bomb: Limiting Antibiotic Resistance in Long Term Care

Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
Multi-drug resistant organisms (MRDOs), such as Methicillin-resistant Staphylococcus aureus (MRSA), due to antibiotic use are of significant concern. Not only hospitals, but also long-term care facilities, are particularly susceptible to the impact of antibiotic resistance. Dr. Paul Drinka, clinical professor of internal medicine and geriatrics at University of Wisconsin-Madison and the Medical College of Wisconsin-Milwaukee, tells us that one evidence-based approach is to maintain a database of the MRDOs that will help identify clustering of a specific isolate and document a facility's resistance problem, which can then be addressed more precisely. What other specific steps might facilities take to prevent unnecessary use of antibiotics and therefore limit resistance? Dr. Eric Tangalos hosts.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Phase 3 study results of plozasiran in patients with FCS
FCS and SHTG: Are We Meeting the Need?
HF Management for Patients with Comorbid Conditions
Personalizing Care Within the RCC Treatment Paradigm
Navigating Myasthenia Gravis in Adolescents and Young Adults
AI and Hair Loss: Measuring Progress with Data-Driven Insights
Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial
Semaglutide improves walking distance, symptoms and QoL in patients with PAD and T2D
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?